Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study

Iran University of Medical Sciences0 个研究点目标入组 324 人开始时间: 待定最近更新: 2020年10月6日

试验速览

暂无简介。

•Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RT-PCR test for COVID-19
•Requiring hospitalization because of: Patient's oxygen saturation less than 93% OR
•Requiring hospitalization because of: GCS score less than 15 OR
•Requiring hospitalization because of: systolic blood pressure less than 100 or 30 mmHg decrease in systolic blood pressure from the level prior to current illness OR
•Requiring hospitalization because of: renal failure (creatinine 1.5 times the previous measurement in the last 7 days OR
•Requiring hospitalization because of: liver failure (AST and ALT 3 times upper limit of normal)
•Patient's age between 16 and 100 years
•Signed informed consent form.

•Receiving other antiviral medications such as (Kaletra, Ribavirin, Oseltamivir, ...)
•Chronic liver failure
•Chronic Renal Failure
•Patients with acute problems whose survival is expected to be less than 48 hours
•HIV patients
•A history of gastrointestinal bleeding
•Pregnancy and lactation
•QT interval exceeds 500 ms

发起方